Bristol Myers Squibb's Investigational LPA1 Antagonist Reduces Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2 Study finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Phase 2 study shows 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 62% relative reduction in the rate of decline in percent predicted forced vital capacity versus. | May 22, 2023
PRINCETON - Bristol Myers Squibb today announced that the European Commission has approved Sotyktu , a first-in-class, selective tyrosine kinase 2 inhibitor, for the treatment of adults with. | March 29, 2023
Sotyktu demonstrated superior efficacy in improving skin clearance over placebo and twice-daily Otezla® , with a well-tolerated safety profile, in the pivotal Phase 3 POETYK PSO clinical. | March 28, 2023